查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球臨床風險分組解決方案市場 - 2023-2030年
市場調查報告書
商品編碼
1290354

全球臨床風險分組解決方案市場 - 2023-2030年

Global Clinical Risk Grouping Solutions Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球臨床風險分組解決方案的市場規模在2022年達到6.0431億美元，預計到2030年將見證有利可圖的成長，達到16.5883億美元。在預測期間（2023-2030年），該市場的年復合成長率為13.9%。醫療保健的風險管理是一套複雜的系統、流程、程序和報告結構，旨在檢測、監測、評估、減輕和預防病人的風險。

臨床風險分組解決方案的市場受到以下因素的驅動：基於價值的護理、醫療成本上升、人口健康管理、數據分析和技術、監管和報銷變化、改善護理協調以及以病人為中心的方法。

臨床風險分組解決方案市場有幾個制約因素，會影響其發展。這些因素包括成本和預算限制、對變革的抵制、分散的醫療系統、數據隱私和安全問題、有限的意識和培訓，以及監管和法律挑戰。

市場動態

對基於價值的護理的關注不斷增加

基於價值的護理是一種強調在控製成本的同時提高病人療效的模式。它將醫療系統的重點從收費服務方式轉移到以價值為基礎的護理，獎勵品質、效率和病人滿意度。

臨床風險解決方案在識別和管理可能影響患者療效的風險方面發揮了關鍵作用。這些解決方案幫助醫療機構監測品質指標，確定需要改進的領域，並實施戰略以減少風險和加強病人安全。

它們還可以促進有效的護理協調和過渡，執行績效測量和報告，成本控制和效率，以及人口健康管理。這些解決方案可以幫助醫療機構實施積極主動的戰略，以防止不良事件的發生，減少再入院，並改善整體人口健康狀況。

監管和法律挑戰

醫療機構的臨床風險解決方案面臨各種監管和法律挑戰，這是阻礙市場發展的主要因素。監管和法律方面的挑戰，如數據隱私和安全、監管合規、標準化和互操作性。

數據隱私法規，如《一般數據保護條例》（GDPR）和《健康保險可攜性和責任法案》（HIPAA），對於解決方案供應商來說，確保其系統符合這些法規是至關重要的。法規遵從要求醫療機構報告不良事件、事件管理和品質報告。

由於缺乏統一的數據格式、術語和通訊協議，標準化和互操作性可能具有挑戰性。解決方案供應商應努力實現互操作性標準，並與其他利益相關者合作，以確保臨床風險解決方案和現有醫療IT基礎設施之間的順利整合和數據共享。

COVID-19影響分析

COVID-19大流行對臨床風險分組解決方案市場產生了重大影響，人們更加關注病人安全，更多地採用遠程醫療和遠程監控服務，並增強了數據分析和監控能力。這導致了對能夠幫助識別和減少與傳染病和其他不良事件有關的風險的臨床風險解決方案的更大需求。

遠程醫療和遠程監測服務也得到了擴展，具有強巨量資料分析能力的臨床風險解決方案在追踪和分析COVID-19相關數據方面發揮了作用，使醫療機構和公共衛生機構能夠有效地應對這場危機。這場大流行需要監管方面的變化和增加醫療服務的靈活性。為確保安全，實施了遠程工作政策和虛擬協作工具。

俄烏衝突分析

俄烏衝突對兩國的臨床風險分組解決方案市場產生了重大影響，包括醫療基礎設施的中斷、醫療專業人員的遷移、有限的財政資源、監管和法律挑戰、數據交換和互操作性的中斷，以及地緣政治不穩定導致的不確定市場環境。醫療機構和解決方案供應商可能需要駕馭不斷變化的法規，並確保他們的解決方案與不斷變化的環境相一致。戰爭也對這兩個國家的臨床試驗產生了負面影響。

目錄

第一章：方法和範圍

  • 研究方法
  • 報告的研究目標和範圍

第二章：定義和概述

第三章：執行摘要

  • 按產品抽查
  • 按部署情況分類
  • 按終端用戶分類
  • 按地區分類

第四章：動態變化

  • 影響因素
    • 驅動因素
      • 對以價值為基礎的護理越來越重視
    • 限制因素
      • 監管和法律挑戰
    • 機會
    • 影響分析

第五章：行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 監管分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情況
    • COVID-19期間的情況
    • COVID-19之後的情況
  • 在COVID-19期間的定價動態
  • 需求-供應譜系
  • 大流行期間與市場有關的政府計劃
  • 製造商的戰略計劃
  • 結語

第七章：按產品分類

  • 數據分析
  • 儀表板和數據可視化工具
  • 風險報告解決方案

第8章：按部署分類

  • 公共雲端
  • 私有雲端
  • 混合雲端

第九章：按終端用戶分類

  • 醫療服務提供者
  • 臨床研究機構
  • 製藥和生物技術公司
  • 其他

第十章：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 亞太其他地區
  • 中東和非洲

第11章：競爭格局

  • 競爭格局
  • 市場定位/佔有率分析
  • 合併和收購分析

第十二章：公司簡介

  • 3M Company
    • 公司概述
    • 產品組合和說明
    • 財務概況
    • 主要發展情況
  • Optum Inc.
  • Conduent Inc.
  • Lightbeam Health Solutions
  • Health Catalyst
  • Change Healthcare
  • Milliman Inc.
  • COTIVITI Inc.
  • Episource
  • Med-IQ Inc

第十三章：附錄

簡介目錄
Product Code: HCIT5267

Market Overview

The Global Clinical Risk Grouping Solutions Market size reached US$ 604.31 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 1,658.83 million by 2030. The market is exhibiting at a CAGR of 13.9% during the forecast period (2023-2030). Risk management in healthcare is a complex set of systems, processes, procedures, and reporting structures designed to detect, monitor, assess, mitigate, and prevent risks to patients.

The market for clinical risk grouping solutions is driven by factors such as value-based care, rising healthcare costs, population health management, data analytics and technology, regulatory and reimbursement changes, improved care coordination, and a patient-centric approach.

The clinical risk grouping solutions market has several restraints that can affect its development. These include cost and budgetary constraints, resistance to change, fragmented healthcare systems, data privacy and security concerns, limited awareness and training, and regulatory and legal challenges.

Market Dynamics

Rising Focus On Value-Based Care

Value-based care is a model that emphasizes improving patient outcomes while controlling costs. It shifts the healthcare system's focus from a fee-for-service approach to value-based care that rewards quality, efficiency, and patient satisfaction.

Clinical risk solutions play a crucial role in identifying and managing risks that could compromise patient outcomes. These solutions help healthcare organizations monitor quality metrics, identify areas for improvement, and implement strategies to mitigate risks and enhance patient safety.

They can also facilitate effective care coordination and transitions, perform performance measurement and reporting, cost containment and efficiency, and population health management. These solutions can help healthcare organizations implement proactive strategies to prevent adverse events, reduce hospital readmissions, and improve overall population health outcomes.

Regulatory and Legal Challenges

Clinical risk solutions in healthcare settings face a variety of regulatory and legal challenges, the main factor hampering the market. The regulatory and legal challenges such as data privacy and security, regulatory compliance, and standardization and interoperability.

Data privacy regulations such as the General Data Protection Regulation (GDPR) and the Health Insurance Portability and Accountability Act (HIPAA) are essential for solution providers to ensure their systems comply with these regulations. Regulatory compliance requires healthcare organizations to report adverse events, incident management, and quality reporting.

Standardization and interoperability can be challenging due to a lack of uniform data formats, terminology, and communication protocols. Solution providers should work towards interoperability standards and collaborate with other stakeholders to ensure smooth integration and data sharing between clinical risk solutions and existing healthcare IT infrastructure.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the clinical risk grouping solutions market, with the increased focus on patient safety, increased adoption of telehealth and remote monitoring services, and enhanced data analytics and surveillance capabilities. This has led to a greater demand for clinical risk solutions that can help identify and reduce risks associated with infectious diseases and other adverse events.

Telehealth and remote monitoring services have also been expanded, and clinical risk solutions with robust data analytics capabilities were instrumental in tracking and analyzing COVID-19-related data, enabling healthcare organizations and public health agencies to respond effectively to the crisis. The pandemic necessitated regulatory changes and increased flexibility in healthcare delivery. Remote work policies and virtual collaboration tools were implemented to ensure safety.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict has had a significant impact on the clinical risk grouping solutions market in both countries including disruption of healthcare infrastructure, displacement of healthcare professionals, limited financial resources, regulatory and legal challenges, data exchange and interoperability disruption, and an uncertain market environment due to geopolitical instability. Healthcare organizations and solution providers may need to navigate evolving regulations and ensure their solutions align with the changing landscape. The war also negatively impacted the clinical trials in both countries.

Segment Analysis

The global clinical risk grouping solutions market is segmented based on product, deployment, end-user, and region.

Based on Product, Dashboard And Data Visualization Tools Segment is Expected To Dominate The Market Share

Based on the product, the dashboard and data visualization tools segment is expected to dominate the market share of 38.7% during the forecast period due to its ability to predict payment processes, payment risk, and ease of comprehension of clinical data. The demand for modern technologies such as big data and AI in the healthcare industry and increased initiatives to reduce the prices of healthcare services are expected to drive market expansion. In addition, rising chronic illness prevalence and increased use of cloud services in data management are likely to drive growth in the worldwide clinical risk grouping solutions market.

Geographical Analysis

North America Accounted for Approximately 40.2% of the Market Share in 2022 Due To Technologically Advanced Healthcare Infrastructure

North America holds the largest market share in the clinical risk grouping solutions market due to its technologically advanced healthcare infrastructure. Several factors contribute to North America's dominance in this market such as advanced healthcare systems, regulatory environment, financial resources, research and development, quality and patient safety, and emphasis on quality and patient safety.

These factors enable healthcare organizations in the region to readily adopt and implement clinical risk solutions to enhance patient safety and risk management. North American healthcare systems place a strong emphasis on quality improvement and patient safety in the clinical risk grouping solutions market.

Competitive Landscape

The major global players in the market include: 3M Company, Optum Inc., Conduent Inc., Lightbeam Health Solutions, Health Catalyst, Change Healthcare, Milliman Inc., COTIVITI Inc., Episource, and Med-IQ Inc.

Why Purchase the Report?

  • To visualize the global clinical risk grouping solutions market segmentation based on product, deployment, end-user, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of clinical risk grouping solutions market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global clinical risk grouping solutions market report would provide approximately 54 tables, 46 figures, and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Deployment
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising focus on value-based care
    • 4.1.2. Restraints
      • 4.1.2.1. Regulatory and legal challenges
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Data Analytics*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Dashboard and Data Visualization Tools
  • 7.4. Risks Reporting Solutions

8. By Deployment

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment
    • 8.1.2. Market Attractiveness Index, By Deployment
  • 8.2. Public Cloud*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Private Cloud
  • 8.4. Hybrid Cloud

9. By End-User

  • 9.1. Healthcare service providers
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Clinical Research Organizations
  • 9.3. Pharmaceutical and Biotech Firms
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. 3M Company*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Optum Inc.
  • 12.3. Conduent Inc.
  • 12.4. Lightbeam Health Solutions
  • 12.5. Health Catalyst
  • 12.6. Change Healthcare
  • 12.7. Milliman Inc.
  • 12.8. COTIVITI Inc.
  • 12.9. Episource
  • 12.10. Med-IQ Inc

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us